True North Therapeutics Inc.'s TNT009 inhibits an upstream target in the classical complement pathway that could lead to greater efficacy and an improved safety profile relative to more advanced complement inhibitors. The single-asset company is focusing on complement-mediated Orphan disorders.

The complement system is a cascade of enzymes within the innate immune system that facilitates the destruction of pathogens, but is up-regulated in many inflammatory diseases.